Answers are grounded in this paper and cite their sources.
: Cutaneous delivery of VSD from micelle-based formulations might enable targeted, topical treatment of superficial BCC with minimal risk of systemic exposure.
No takes yet. Share an insight, caveat, or question.
Kandekar et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: